PRIMARY STUDY

Cannabinoids and Chronic Liver Diseases

Key Findings:  This review suggests that certain pathways in the endocannabinoid system (eCBS) of the liver may provide therapeutic options for certain chronic liver diseases(CLD). Experimental models and observational studies of CLD suggest that cannabis and cannabinoids may be hepatoprotective CLDs through multiple pathways.

Type of Study:  Meta-analysis

Study Result:  Positive

Study Location(s):  Canada, Italy

Year of Pub:  2020


Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabidiolic Acid (CBD-a), Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Cannabinoid (unspecified), Endocannabinoid (unspecified), Tetrahydrocannabivarin (THCV)

Phytocannabinoid Source:  Unspecified

Receptors Studied:  CB1, CB2, GPCR 18, GPCR 55, TRPA1, TRPV1, TRPV2, TRPM8, PPAR - Alpha, PPAR - Gamma, TRPs, PPARs

Ligands Studied:  Pro-inflammatory cytokines